GlassScriptPhysician profile
Amber N Walker
NPI 1811448202
$2,537.16
in general payments reported to CMS, 2019-2025
32 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $588 · 2023: $554 · 2024: $677 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $301.21 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $291.42 | 2021-2024 | Airsupra, Farxiga |
| Abbvie INC. | $278.52 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.87 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $167.52 | 2021-2024 | Verquvo, Lagevrio |
| Ironshore Pharmaceuticals INC. | $162.86 | 2024 | |
| Dexcom, INC. | $139.90 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $114.68 | 2021-2023 | |
| Lundbeck LLC | $74.87 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $72.76 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $70.60 | 2021-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $66.31 | 2021-2022 | |
| Lilly USA, LLC | $61.39 | 2021-2023 | Mounjaro |
| Boston Scientific Corporation | $53.15 | 2024-2025 | Watchman Access System, General - Pain Management |
| Amgen INC. | $50.60 | 2021-2023 | Otezla, Repatha |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.65 | 2021-2023 | Jardiance, Synjardy |
| Jazz Pharmaceuticals INC. | $35.37 | 2021 | |
| Astellas Pharma US INC | $30.55 | 2023 | Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $29.15 | 2023 | Rexulti |
| Corcept Therapeutics | $27.97 | 2024 | Korlym |
| Teva Pharmaceuticals USA, INC. | $27.51 | 2025 | Uzedy |
| Gilead Sciences, INC. | $25.59 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.85 | 2024 | Caplyta |
| Ardelyx, INC. | $23.58 | 2025 | Ibsrela |
| Grt US Holding, INC. | $17.99 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.75 | 2022 | |
| Shield Therapeutics INC | $17.48 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $16.17 | 2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $14.90 | 2025 | Dupixent |
| Pfizer INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.